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Abstract 
Rationale: Dopamine dysregulation in the prefrontal cortex (PFC) plays an important 
role in cognitive dysfunction in schizophrenia. Sub-chronic phencyclidine (scPCP) 
treatment produces cognitive impairments in rodents and is a thoroughly validated 
animal model for cognitive deficits in schizophrenia.  The aim of our study was to 
investigate the role of PFC dopamine in scPCP-induced deficits in a cognitive task of 
relevance to the disorder, novel object recognition (NOR).  Methods: Twelve adult 
female Lister Hooded rats received scPCP (2 mg/kg) or vehicle via the intraperitoneal 
route twice daily for seven days, followed by seven days washout.  In vivo microdialysis 
was carried out prior to, during and following the NOR task.  Results:  Vehicle rats 
successfully discriminated between novel and familiar objects and this was 
accompanied by a significant increase in dopamine in the PFC during the retention trial 
(P<0.01).  scPCP produced a significant deficit in NOR (P<0.05 vs. control) and no 
PFC dopamine increase was observed. Conclusions:  These data demonstrate an 
increase in dopamine during the retention trial in vehicle rats that was not observed in 
scPCP-treated rats accompanied by cognitive disruption in the scPCP group. This novel 
finding suggests a mechanism by which cognitive deficits are produced in this animal 
model and support its use for investigating disorders in which PFC dopamine is central 
to the pathophysiology. 
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Introduction 
The novel object recognition (NOR) task was developed by Ennaceur and Delacour and 
is based on the natural propensity of rats to explore novel objects (Ennaceur and 
Delacour, 1988).  It is a non-rewarded, ethologically relevant test of visual object 
recognition memory (Puma et al., 1998).  Indeed, NOR has been listed by the 
Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) initiative as relevant for studying visual learning and memory deficits in 
schizophrenia (Young et al., 2009). Such tests of visual recognition memory are 
increasingly being used to detect novel drugs for improvement of cognitive dysfunction 
in schizophrenia and other human disorders including Alzheimer’s disease, Parkinson’s 
disease, and Autism Spectrum Disorder (Grayson et al., 2015).  
The brain regions thought to be involved in object recognition memory depend 
on the length of the inter-trial interval (ITI).  We have recently shown that normal 
unimpaired animals lose the ability to discriminate objects following an ITI of 6 hours 
(McLean et al., 2016). Rats with hippocampal lesions exhibit impairments in object 
recognition following long ITIs (>15 min), but not short intervals of <15 min (Clark et 
al., 2000).  Although much of the evidence indicates a critical role for the perirhinal 
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cortex in object recognition memory following short ITIs (Gaffan and Murray, 1992; 
Meunier et al., 1993; Ennaceur et al., 1996; Brown and Aggleton, 2001; Hannesson et 
al., 2004), research also suggests that the prefrontal cortex (PFC) may also contribute to 
recognition memory.  PFC neurons have been shown to relay information concerning 
the relative familiarity of individual stimuli (Xiang and Brown, 2004), and damage to 
this area has been shown to impair recognition memory (Kolb et al., 1994; Ragozzino et 
al., 2002).  More recently, fMRI studies have demonstrated that disruption of mPFC 
activation is correlated with impairments in recognition memory (Zanto et al., 2011). 
However, there is also conflicting evidence showing that cytotoxic lesions of the mPFC 
spared object recognition performance following a 10 min ITI (Yee, 2000); this further 
highlights the need to further investigate the role of the PFC in this behavioural task. 
Dysfunction in the glutamatergic system is a prominent hypothesis for the 
pathogenesis of schizophrenia (Olney et al., 1999). As a result of this hypothesis, many 
pre-clinical animal models for schizophrenia are now based on the administration of 
NMDA receptor antagonists such as phencyclidine, MK-801 and ketamine (Neill et al., 
2014).  The non-competitive NMDA receptor antagonist, phencyclidine (PCP) has been 
shown to produce enduring cognitive deficits similar to those observed in schizophrenia 
in rodents (Javitt and Zukin, 1991; Meltzer et al., 2013) particularly when administered 
sub-chronically-sc (Jentsch and Roth, 1999; Neill et al., 2010; Rajagopal et al., 2014; 
Janhunen et al., 2015).  Indeed, we have consistently shown in our laboratory that a 
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scPCP treatment regimen produces long lasting and robust cognitive impairments in 
several cognitive domains of relevance to schizophrenia, including visual learning 
(McLean et al., 2011; Neill et al., 2016), reasoning and problem solving (McLean et al., 
2012; Neill et al., 2016; McLean et al., 2010), executive function (McLean et al., 2012) 
and attention/vigilance (Barnes et al., 2016; Barnes et al., 2012).   
While newer compounds for cognition and negative symptoms, the major unmet 
clinical needs in schizophrenia, targeting mechanisms such as the metabotropic 
glutamate receptor 2/3 subtype, phosphodiesterase subtype 10, glycine transporter 
subtype 1 and the α7 nicotinic acetylcholine receptor have been the subject of intense 
drug discovery and development efforts; there is still a lack of success in Phase III 
clinical trials (Dunlop and Brandon, 2015), Dopamine hypofunction in the PFC is 
thought to have a major role in the aetiology of negative symptoms and cognitive 
dysfunction in schizophrenia (Jentsch and Roth, 1999; Abi-Dargham and Moore, 2003; 
Goldman-Rakic et al., 2004; Stone et al., 2007).  scPCP has been shown to reduce 
dopamine utilisation in the PFC and nucleus accumbens (Jentsch et al., 1997).  
Furthermore, it has been shown that the atypical antipsychotics, sertindole and 
risperidone, increase extracellular dopamine in rat mPFC and nucleus accumbens (Mork 
et al., 2009) and improve a scPCP-induced deficit in NOR memory (Grayson et al., 
2007; Idris et al., 2010).  We have also previously shown that targeting dopamine D1 
receptors ameliorates the effects of scPCP treatment in NOR, reversal learning and the 5 
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choice continuous performance test (McLean et al., 2009; Barnes et al., 2016), further 
implicating the role of dopamine in prefrontal-based cognitive tasks. 
As yet, the role of dopamine in scPCP-induced cognitive disruption remains to 
be fully established.  Therefore, the aim of this study was to investigate the interaction 
between the NOR deficit induced by our scPCP treatment regime and levels of PFC 
dopamine. This was achieved by combining in vivo microdialysis in freely moving 
behaving animals to assess the changes in PFC dopamine at the same time as observing 
a cognitive deficit.   
 
 
Materials and Methods 
 
Subjects and drug treatment 
Twelve adult female Lister Hooded rats (Charles River, UK) were housed in groups of 
2-3 and weighed 220-250 g at the start of the dosing regimen and 240-270 g at the time 
of surgery and behavioural testing.  Animals were housed under standard laboratory 
conditions at a temperature of 20°C (±1°C) and humidity of 50±5%.  They were 
maintained on a 12-h/12-h light/dark cycle (lights on at 0700 hours) and experimental 
procedures were performed during the light phase.  Rats had free access to food and 
water at all times, except during NOR testing and habituation.  Rats were treated with 2 
mg/kg PCP (phencyclidine hydrochloride, Sigma, UK; n = 5) or vehicle (0.9 % saline; n 
= 7), twice daily for 7 days; this was followed by a 7-day washout period.  All 
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experiments were performed according to the Animals (Scientific Procedures) Act, 
1986, and with approval from the University of Leicester Animal Ethics Committee. 
 
Surgery and microdialysis 
Rats were anaesthetised with isoflurane (1-3% isoflurane in O2: 1 litre/min) and 
stainless steel guide cannulae (o.d., 890 μm; i.d., 685 μm; length 10 mm: Coopers 
Needle Works, Birmingham, UK) were stereotaxically implanted into the brain, aimed 
at the PFC, figure 1.  Following recovery from surgery (≥7 days), dialysis probes were 
inserted into the guide cannulae to lie in the PFC with stereotaxic co-ordinates (tip 
position mm from Bregma: H, +3.2; Tr, -0.5; V, -5.4; (Paxinos and Watson, 1998)).  
Microdialysis probes were constructed in house and checked for flow rate integrity and 
leaks before implantation (Young et al., 1998).  At least one hour after implantation of 
the probe, animals were connected to the delivery system, and perfusion with artificial 
cerebrospinal fluid (mM: NaCl, 145; KCl, 3.3; MgSO4, 2.4; KH2PO4, 1.25; CaCl2, 1.85: 
2 μl/min flow rate) commenced immediately.  Following equilibration for 1 hour, 
dialysate samples were collected consecutively for 10 min into 2 μl of 1.0 M H3PO4 (to 
minimise oxidation).  The first four samples (40 min) were used to determine basal 
dopamine levels in the dialysates.  Samples were then collected during the NOR test 
during the 10 min habituation to the box, acquisition, inter-trial interval (ITI) and 
retention phases (all 10 min); in addition, 3 samples were collected post-testing (30 
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min).  At the end of the collection period, animals were killed by anaesthetic overdose 
(sodium pentobarbitone, JML, Southampton, UK) and cervical dislocation.  The brains 
were removed and stored in 4% formalin and placement of the probes confirmed using 
cresyl violet staining. 
   
Novel object recognition testing 
Rats were tested in the NOR task as described in detail previously (McLean et al., 
2011), with the exception that 10-min trials were used with a 10 min ITI (not 3-min 
trials with a 1 min ITI our usual protocol) in order to give enough time to collect the 
required sample for HPLC analysis. Rats were habituated to the test arena for 30 min 
for 3 days prior to the test day.  Following a 10-min habituation session on the day of 
testing, each rat was placed in the NOR chamber and exposed to two identical objects 
for a period of 10 min.  The rats were then returned to their home cage for an ITI of 10 
min; the entire box was cleaned with 10% ethanol, both objects removed and one 
replaced with an identical familiar copy and one with a novel object. Following the ITI, 
rats were returned to explore the familiar and a novel object in the test arena for a 10-
min retention trial. All experiments were video recorded for subsequent behavioural 
analysis by an experimenter blinded to the treatment. Locomotor activity was also 
recorded; this was evaluated by scoring the total number of sectors or line crossings by 
the animal in acquisition and retention trial.  The exploration time (s) of each object in 
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each trial was recorded manually using two stopwatches and the discrimination index 
(DI) was calculated: DI= (time exploring the novel object (s) – time exploring the 
familiar object) / total time exploring both novel and familiar objects.  The DI 
represents the difference in exploration time expressed as a proportion of the total time 
spent exploring the two objects in the retention trial. A value of 1 would show that rats 
explored only the novel object; a value of -1 would show that rats only explored the 
familiar object and a value of 0 indicates exploration of both objects equally. 
 
 HPLC detection of dopamine 
After collection, all dialysate samples (1-11) were analysed to determine the 
concentration of dopamine in each sample by HPLC with electrochemical detection.  
Samples (15 μl) were injected onto the column using a Spark Triathlon refrigerated 
autosampler (Presearch, UK).  The mobile phase consisted of 75 mM NaH2PO4, 1.1 
mM octanesulfonic acid, 1 mM EDTA, 10% methanol, pH 3.7 and was pumped at 110 
μl/min using a Rheos 4000A pump (Presearch, UK), and separation was achieved using 
a 150 mm × 1.0 mm LUNA C18(2) 5 µm column (Phenomenex, UK).  Dopamine 
(retention time of approximately 12 min) concentrations were calculated with reference 
to standards at 1, 10, and 100 nM.  Data were collected and analyzed using Chrom 
Perfect Analysis v5.5.4 (Justice Laboratories, NJ, USA) PC-based integrator.  All 
chemicals were supplied by Sigma Chemicals (Poole, UK) and were HPLC grade.   
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Data and statistical analysis 
The NOR data are expressed as mean exploration time ± S.E.M. Student’s paired t-test 
was performed to compare time spent exploring the familiar versus the novel object. 
The discrimination index (DI) values are expressed as mean ± S.E.M. Locomotor 
activity (LMA) data are expressed as mean ± S.E.M of the total number of lines crossed 
during the acquisition and retention trials.  Analysis of the DI values and total LMA 
were performed using independent t-tests, vehicle compared with the scPCP group. 
The basal concentration of dopamine was calculated from the four samples taken 
prior to behavioural testing; subsequent samples were then expressed as percent of 
basal.    Microdialysis data were analysed using a repeated measures two-way ANOVA 
with stage of task as a within subjects factor (habituation, acquisition, ITI, retention, 3 
post-test) and treatment (vehicle or scPCP) as a between subjects factor.  This was 
followed by planned pair-wise comparisons with Bonferroni adjustment.  All statistical 
analyses were performed using SPSS (version 22). 
 
Results 
Initially the groups consisted of 7 vehicle-treated and 5 scPCP-treated rats; however 2 
vehicle-treated rats were excluded due to technical problems with HPLC, these rats 
were removed from all analyses, therefore the final treatment groups were both n=5.  
11 
 
Following cresyl violet staining, the locations of the probes were verified.  All probes 
were located within the PFC at Bregma 2.7 to 3.2 mm. An example image of probe 
location is shown in figure 1.  
Paired t-tests revealed that there was no significant difference between the time 
spent exploring the two identical objects during the acquisition trial in either vehicle or 
scPCP-treated rats (data not shown).  In the retention trial, vehicle-treated rats explored 
the novel object more than the familiar object, although this effect was not significant (P 
= 0.11; table 1); there was no significant difference in exploration of the novel and 
familiar object in scPCP-treated rats (table 1).  However, an independent t-test revealed 
a significant difference in the DI (t[9] = 2.87; P = 0.018).  The DI for the scPCP-treated 
group was significantly reduced from 0.60 in the vehicle treated group to 0.25 (figure 
2).  Moreover, one-sample t-tests showed that the DI was significantly different from 
zero (no discrimination) in the saline treated animals (t[5] = 8.41; P < 0.001), but not in 
the scPCP pre-treated group (t[4] = 2.34; P = 0.78). Independent t-tests showed no 
significant effect on locomotor activity assessed by the total number of line crossings in 
the acquisition and retention trials (76.5 ± 19.6 in vehicle-treated rats compared to 97 ± 
16.9 in scPCP-treated rats; data not shown). 
Following the behavioural experiments, HPLC was carried out, therefore the 
groups for dopamine analysis were vehicle (n=5) and scPCP (n=5).  The mean of the 4 
baseline concentrations prior to behavioural testing was calculated.  An independent t-
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test revealed no significant difference between basal levels in the two groups (vehicle, 
3.3 ± 2.0 nM; scPCP, 2.9 ± 0.6 nM).  Data were subsequently expressed as percent of 
basal (figure 3).  A two-way repeated measures ANOVA with stage of test as the within 
subjects factor and treatment as the between subjects factor revealed no significant 
interaction (F[4,32] = 1.89; P = 0.13).  However, planned pair-wise comparisons with 
Bonferroni adjustment revealed a selective and significant increase in dopamine levels 
in vehicle treated rats in the retention phase compared to basal (290 ± 120 % of basal; 
P<0.01), however, this effect was not observed in scPCP-treated rats (113 ± 19 % of 
basal). 
 
Discussion 
This study aimed to investigate the role of prefrontal dopamine in deficits in NOR task 
performance in the scPCP animal model for schizophrenia.  The main findings suggest 
that an increase in dopamine in the PFC during the retention trial may be beneficial for 
NOR performance either by increasing the preference for the novel object or for aiding 
the recall of memory for the familiar object.  During the acquisition trial of the NOR 
task there was no difference in the exploration time of the two identical objects in either 
vehicle or scPCP-treated rats.  Conversely, in the retention trial, calculation of the DI 
revealed that vehicle-treated rats could discriminate the novel from familiar object in the 
retention trial, suggesting that they remembered the familiar object.  However, this 
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discrimination was not observed when comparing time spent at the novel versus the 
familiar object; this lack of discrimination is likely due to the low n numbers and 
subsequent large variability within the group.  In the scPCP-treated rats however, the 
object exploration data and the DI revealed that rats could not discriminate between the 
novel and familiar objects, suggesting that scPCP-treated rats did not remember the 
familiar object.  This scPCP-induced deficit in NOR (and its attenuation by 
dopamine/serotonin receptor antagonist drugs for schizophrenia and novel targets) is 
supported by many previous studies in our laboratory (McLean et al., 2011; Neill et al., 
2010; Neill et al., 2016) and elsewhere.  These results are also consistent with previous 
reports from others demonstrating scPCP treatment in rats impairs object recognition 
(Le Cozannet et al., 2010; Redrobe et al., 2012; Miyauchi et al., 2016).  In addition, it 
has been shown that PCP, when given in varying dosing regimens, produced deficits in 
object recognition in mice (Nagai et al., 2009; Hashimoto et al., 2005; Horio et al., 
2013; Rajagopal et al., 2016).   
The concentration of dopamine in the PFC revealed that the basal levels in 
vehicle and scPCP-treated rats were similar.  Concentrations were also comparable 
during all stages of the NOR task with the exception of the retention trial, in which a 
large increase in dopamine was observed in the vehicle treated group.  This suggests 
that dopamine in the PFC is important for retrieval of object recognition memory, not 
encoding or consolidation, as levels remained comparable to baseline during the 
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acquisition trial and ITI.  In contrast, this increase in prefrontal dopamine was absent in 
the scPCP-treated group.  In collaboration with the Meltzer laboratory we conducted a 
similar study some years ago (published in abstract form only). There were some 
differences as in that study we used female Long Evans rats, 15 min time bins, also 
investigated hippocampus and did not include so many time points (Snigdha et al., 
2008). However, our current findings confirm that early result and show impaired 
performance in retention accompanied by a lack of increase in dopamine in the PFC.  
It has been shown that many dopamine/serotonin receptor antagonist drugs for 
schizophrenia such as sertindole and risperidone (Mork et al., 2009), and clozapine, 
olanzapine and quietapine (Tanda et al., 2015) increase extracellular dopamine in male 
rat mPFC.   More specifically, we have shown that intracortical perfusion of the 
dopamine D1-like receptor agonist, SKF-38393, in drug-naïve awake male rats 
decreased glutamate and increased GABA release in the mPFC, potentially restoring the 
balance between glutamate and GABA (Harte and O'Connor, 2004). We have also 
established that SKF-38393, when given systemically, can reverse the scPCP-induced 
deficit in NOR in female rats (McLean et al., 2009).  This is supported by data reporting 
that microinfusion of the dopamine D1-like receptor antagonist SCH-23390 into the rat 
mPFC produced a deficit in NOR (Rossato et al., 2013; Clausen et al., 2011).  
Conversely in a recent study, microinfusion of the D1-like receptor agonist SKF81297 
into the mPFC induced a dose-related impairment in object recognition encoding and 
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retrieval (Pezze et al., 2015). Although these results appear conflicting, the authors 
propose that NOR memory requires an optimal level of D1 receptor stimulation in the 
mPFC and may reflect an inverted U-shaped function (Pezze et al., 2015).  The role of 
dopamine in the PFC has been further investigated using other selective dopamine 
receptor agonists and antagonists. Bilateral microinjection of the dopamine D3 
antagonist, S33084, into the rat PFC caused a dose-related improvement in NOR, while 
intra-striatal injection had no effect (Watson et al., 2012).  In contrast, bilateral 
microinjection of the preferential D2 antagonist, L741,626, into the PFC (but not 
striatum) caused a dose-related impairment in NOR in rats (Watson et al., 2012). Taken 
together, these results show that pharmacological manipulation of dopamine levels in 
the PFC can have either beneficial or detrimental effects on object recognition memory, 
in that they follow an inverted U-shaped relationship. 
One limitation of the present study is low n numbers, as two vehicle-treated rats 
had to be excluded from the final analysis due technical problems with the HPLC 
analysis; therefore, the final number of rats (5 vehicle and 5 PCP) was low for a 
behavioural study.  Previous studies in this laboratory have found a robust and 
reproducible deficit with scPCP in NOR when using 8-10 rats (Neill et al., 2010).  Due 
to the low number of rats used here, the error within the groups is large; this is 
particularly apparent in the vehicle group during exploration of the novel object and 
may explain the lack of a significant difference in exploration times in the retention 
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trial.  However, this is a preliminary study and clearly requires verification with a larger 
sample size and more detailed analysis of other neurotransmitters. 
In summary, these current results demonstrate recruitment of dopamine in the 
PFC when rats are exposed to two objects, one new and one familiar. As there was no 
increase in PFC dopamine in the acquisition trial, these new, but preliminary, data 
support the hypothesis that, for rats to recall information about the familiar object they 
must recruit PFC dopamine, an effect which is absent in scPCP treated rats which may 
explain why they cannot discriminate the novel form familiar object.  A link between 
dopamine and cognition has been observed in patients with schizophrenia, in that low 
dopamine turnover was associated with poor verbal recall (Oades et al., 2005), albeit 
dopamine was measured in plasma and not brain. In conclusion our findings provide 
evidence that the scPCP model has considerable validity for investigating cognitive 
deficits in schizophrenia. Furthermore, the ability of novel compounds to restore this 
PFC dysfunction (and the NOR deficit) may well reveal compounds with good efficacy 
in the clinic to overcome cognitive disturbances observed in schizophrenia, a current 
unmet need.  
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Table and Figures 
 
Table 1: The effect of treatment with vehicle or scPCP on exploration times of objects 
in the NOR task 
 
Exploration time (s) 
 
Acquisition Retention 
Group Left Right Novel Familiar 
Vehicle 20.7 ± 6.6 19.8 ± 5.1 24.7 ± 11.4 6.0 ± 2.3 
PCP 24.8 ± 3.6 24.2 ± 3.5 27.0 ± 6.2 17.2 ± 4.0 
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Figure 1 
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Legends 
 
 
Table 1: The effect of treatment with vehicle or scPCP (2 mg/kg, twice daily for 7 days, 
i.p. followed by 7 days drug free) in the NOR task.  Data are shown as mean exploration 
times ± s.e.m (n=5 per group).  There were no significant differences between time 
spent exploring the novel and familiar object in either treatment group. 
 
Figure 1:  Microdialysis probe placement.  Top: coronal image from Watson and 
Paxinos (1998), Bregma 2.7 mm showing PFC regions.  Bottom: Photograph taken at 
x4 magnification following Cresyl violet staining. The solid shaded rectangle represents 
the position of the cannula; the dotted line represents the tip position. 
 
Figure 2: The effect of treatment with vehicle or scPCP (2 mg/kg, twice daily for 7 
days, i.p. followed by 7 days drug free) in the NOR task.  Data are shown as mean DI ± 
s.e.m (n=5 per group).  The DI for the scPCP-treated group was significantly reduced 
compared to the vehicle group (*P<0.05). 
 
Figure 3: Relative concentrations of dopamine in the PFC expressed as percent basal in 
vehicle and scPCP-treated rats at each stage of the NOR task.  Data are shown as mean 
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percent of basal ± S.E.M (n=5). **P<0.01 significant increase in dopamine in the 
retention phase compared to basal level. 
 
 
 
 
References 
Abi-Dargham A and Moore H. (2003) Prefrontal DA transmission at D1 receptors and 
the pathology of schizophrenia. Neuroscientist 9: 404-416. 
Barnes SA, Young JW, Bate ST, et al. (2016) Dopamine D1 receptor activation 
improves PCP-induced performance disruption in the 5C-CPT by reducing 
inappropriate responding. Behav Brain Res 300: 45-55. 
Barnes SA, Young JW and Neill JC. (2012) D(1) receptor activation improves vigilance 
in rats as measured by the 5-choice continuous performance test. 
Psychopharmacology (Berl) 220: 129-141. 
Brown MW and Aggleton JP. (2001) Recognition memory: what are the roles of the 
perirhinal cortex and hippocampus? Nat Rev Neurosci 2: 51-61. 
Clark RE, Zola SM and Squire LR. (2000) Impaired recognition memory in rats after 
damage to the hippocampus. J Neurosci 20: 8853-8860. 
Clausen B, Schachtman TR, Mark LT, et al. (2011) Impairments of exploration and 
memory after systemic or prelimbic D1-receptor antagonism in rats. Behav 
Brain Res 223: 241-254. 
Dunlop J and Brandon NJ. (2015) Schizophrenia drug discovery and development in an 
evolving era: Are new drug targets fulfilling expectations? J Psychopharmacol 
29. 
Ennaceur A and Delacour J. (1988) A new one-trial test for neurobiological studies of 
memory in rats. 1: Behavioral data. Behav Brain Res 31: 47-59. 
Ennaceur A, Neave N and Aggleton JP. (1996) Neurotoxic lesions of the perirhinal 
cortex do not mimic the behavioural effects of fornix transection in the rat. 
Behav Brain Res 80: 9-25. 
Gaffan D and Murray EA. (1992) Monkeys (Macaca fascicularis) with rhinal cortex 
ablations succeed in object discrimination learning despite 24-hr intertrial 
23 
 
intervals and fail at matching to sample despite double sample presentations. 
Behav Neurosci 106: 30-38. 
Goldman-Rakic PS, Castner SA, Svensson TH, et al. (2004) Targeting the dopamine D1 
receptor in schizophrenia: insights for cognitive dysfunction. 
Psychopharmacology (Berl) 174: 3-16. 
Grayson B, Idris NF and Neill JC. (2007) Atypical antipsychotics attenuate a sub-
chronic PCP-induced cognitive deficit in the novel object recognition task in the 
rat. Behav Brain Res 184: 31-38. 
Grayson B, Leger M, Piercy C, et al. (2015) Assessment of disease-related cognitive 
impairments using the novel object recognition (NOR) task in rodents. Behav 
Brain Res 285: 176-193. 
Hannesson DK, Howland JG and Phillips AG. (2004) Interaction between perirhinal 
and medial prefrontal cortex is required for temporal order but not recognition 
memory for objects in rats. J Neurosci 24: 4596-4604. 
Harte M and O'Connor WT. (2004) Evidence for a differential medial prefrontal 
dopamine D1 and D2 receptor regulation of local and ventral tegmental 
glutamate and GABA release: a dual probe microdialysis study in the awake rat. 
Brain Res 1017: 120-129. 
Hashimoto K, Fujita Y, Shimizu E, et al. (2005) Phencyclidine-induced cognitive 
deficits in mice are improved by subsequent subchronic administration of 
clozapine, but not haloperidol. Eur J Pharmacol 519: 114-117. 
Horio M, Fujita Y and Hashimoto K. (2013) Therapeutic effects of metabotropic 
glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-
induced cognitive deficits in mice. Fundam Clin Pharmacol 27: 483-488. 
Idris N, Neill J, Grayson B, et al. (2010) Sertindole improves sub-chronic PCP-induced 
reversal learning and episodic memory deficits in rodents: involvement of 5-
HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) 208: 
23-36. 
Janhunen SK, Svard H, Talpos J, et al. (2015) The subchronic phencyclidine rat model: 
relevance for the assessment of novel therapeutics for cognitive impairment 
associated with schizophrenia. Psychopharmacology (Berl) 232: 4059-4083. 
Javitt DC and Zukin SR. (1991) Recent advances in the phencyclidine model of 
schizophrenia. Am J Psychiatry 148: 1301-1308. 
Jentsch JD and Roth RH. (1999) The neuropsychopharmacology of phencyclidine: from 
NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. 
Neuropsychopharmacology 20: 201-225. 
Jentsch JD, Tran A, Le D, et al. (1997) Subchronic phencyclidine administration 
reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-
dependent cognition in the rat. Neuropsychopharmacology 17: 92-99. 
24 
 
Kolb B, Buhrmann K, McDonald R, et al. (1994) Dissociation of the medial prefrontal, 
posterior parietal, and posterior temporal cortex for spatial navigation and 
recognition memory in the rat. Cereb Cortex 4: 664-680. 
Le Cozannet R, Fone KC and Moran PM. (2010) Phencyclidine withdrawal disrupts 
episodic-like memory in rats: reversal by donepezil but not clozapine. Int J 
Neuropsychopharmacol 13: 1011-1020. 
McLean SL, Grayson B, Idris NF, et al. (2011) Activation of alpha7 nicotinic receptors 
improves phencyclidine-induced deficits in cognitive tasks in rats: implications 
for therapy of cognitive dysfunction in schizophrenia. Eur 
Neuropsychopharmacol 21: 333-343. 
McLean SL, Grayson B, Marsh S, et al. (2016) Nicotinic alpha7 and alpha4beta2 
agonists enhance the formation and retrieval of recognition memory: Potential 
mechanisms for cognitive performance enhancement in neurological and 
psychiatric disorders. Behav Brain Res 302: 73-80. 
McLean SL, Idris NF, Grayson B, et al. (2012) PNU-120596, a positive allosteric 
modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic 
phencyclidine-induced cognitive deficit in the attentional set-shifting task in 
female rats. J Psychopharmacol 26: 1265-1270. 
McLean SL, Idris NF, Woolley ML, et al. (2009) D(1)-like receptor activation improves 
PCP-induced cognitive deficits in animal models: Implications for mechanisms 
of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 
19: 440-450. 
McLean SL, Neill JC, Idris NF, et al. (2010) Effects of asenapine, olanzapine, and 
risperidone on psychotomimetic-induced reversal-learning deficits in the rat. 
Behav Brain Res 214: 240-247. 
Meltzer HY, Rajagopal L, Huang M, et al. (2013) Translating the N-methyl-D-aspartate 
receptor antagonist model of schizophrenia to treatments for cognitive 
impairment in schizophrenia. Int J Neuropsychopharmacol 16: 2181-2194. 
Meunier M, Bachevalier J, Mishkin M, et al. (1993) Effects on visual recognition of 
combined and separate ablations of the entorhinal and perirhinal cortex in rhesus 
monkeys. J Neurosci 13: 5418-5432. 
Miyauchi M, Neugebauer NM, Oyamada Y, et al. (2016) Nicotinic receptors and 
lurasidone-mediated reversal of phencyclidine-induced deficit in novel object 
recognition. Behav Brain Res 301: 204-212. 
Mork A, Witten LM and Arnt J. (2009) Effect of sertindole on extracellular dopamine, 
acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a 
comparison with risperidone and exploration of mechanisms involved. 
Psychopharmacology (Berl) 206: 39-49. 
25 
 
Nagai T, Murai R, Matsui K, et al. (2009) Aripiprazole ameliorates phencyclidine-
induced impairment of recognition memory through dopamine D1 and serotonin 
5-HT1A receptors. Psychopharmacology (Berl) 202: 315-328. 
Neill JC, Barnes S, Cook S, et al. (2010) Animal models of cognitive dysfunction and 
negative symptoms of schizophrenia: focus on NMDA receptor antagonism. 
Pharmacol Ther 128: 419-432. 
Neill JC, Grayson B, Kiss B, et al. (2016) Effects of cariprazine, a novel antipsychotic, 
on cognitive deficit and negative symptoms in a rodent model of schizophrenia 
symptomatology. Eur Neuropsychopharmacol 26: 3-14. 
Neill JC, Harte MK, Haddad PM, et al. (2014) Acute and chronic effects of NMDA 
receptor antagonists in rodents, relevance to negative symptoms of 
schizophrenia: a translational link to humans. Eur Neuropsychopharmacol 24: 
822-835. 
Oades RD, Ropcke B, Henning U, et al. (2005) Neuropsychological measures of 
attention and memory function in schizophrenia: relationships with symptom 
dimensions and serum monoamine activity. Behav Brain Funct 1: 14. 
Olney JW, Newcomer JW and Farber NB. (1999) NMDA receptor hypofunction model 
of schizophrenia. J Psychiatr Res 33: 523-533. 
Paxinos G and Watson C. (1998) The rat brain atlas in stereotaxic coordinates. San 
Diego: Academic. 
Pezze MA, Marshall HJ, Fone KC, et al. (2015) Dopamine D1 receptor stimulation 
modulates the formation and retrieval of novel object recognition memory: Role 
of the prelimbic cortex. Eur Neuropsychopharmacol 25: 2145-2156. 
Puma C, Baudoin C and Bizot JC. (1998) Effects of intraseptal infusions of N-methyl-
D-aspartate receptor ligands on memory in an object recognition task in rats. 
Neurosci Lett 244: 97-100. 
Ragozzino ME, Detrick S and Kesner RP. (2002) The effects of prelimbic and 
infralimbic lesions on working memory for visual objects in rats. Neurobiol 
Learn Mem 77: 29-43. 
Rajagopal L, Burgdorf JS, Moskal JR, et al. (2016) GLYX-13 (rapastinel) ameliorates 
subchronic phencyclidine- and ketamine-induced declarative memory deficits in 
mice. Behav Brain Res 299: 105-110. 
Rajagopal L, Massey BW, Huang M, et al. (2014) The novel object recognition test in 
rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 
20: 5104-5114. 
Redrobe JP, Elster L, Frederiksen K, et al. (2012) Negative modulation of GABAA 
alpha5 receptors by RO4938581 attenuates discrete sub-chronic and early 
postnatal phencyclidine (PCP)-induced cognitive deficits in rats. 
Psychopharmacology (Berl) 221: 451-468. 
26 
 
Rossato JI, Radiske A, Kohler CA, et al. (2013) Consolidation of object recognition 
memory requires simultaneous activation of dopamine D1/D5 receptors in the 
amygdala and medial prefrontal cortex but not in the hippocampus. Neurobiol 
Learn Mem 106: 66-70. 
Snigdha S, Li Z, Dai J, et al. (2008) Effect of PCP to attenuate DA efflux in rats 
performing the object recognition task: an in vivo investigation. Society for 
Neuroscience Abstracts. 
Stone JM, Morrison PD and Pilowsky LS. (2007) Glutamate and dopamine 
dysregulation in schizophrenia--a synthesis and selective review. J 
Psychopharmacol 21: 440-452. 
Tanda G, Valentini V, De Luca MA, et al. (2015) A systematic microdialysis study of 
dopamine transmission in the accumbens shell/core and prefrontal cortex after 
acute antipsychotics. Psychopharmacology (Berl) 232: 1427-1440. 
Watson DJ, Loiseau F, Ingallinesi M, et al. (2012) Selective blockade of dopamine D3 
receptors enhances while D2 receptor antagonism impairs social novelty 
discrimination and novel object recognition in rats: a key role for the prefrontal 
cortex. Neuropsychopharmacology 37: 770-786. 
Xiang JZ and Brown MW. (2004) Neuronal responses related to long-term recognition 
memory processes in prefrontal cortex. Neuron 42: 817-829. 
Yee BK. (2000) Cytotoxic lesion of the medial prefrontal cortex abolishes the partial 
reinforcement extinction effect, attenuates prepulse inhibition of the acoustic 
startle reflex and induces transient hyperlocomotion, while sparing spontaneous 
object recognition memory in the rat. Neuroscience 95: 675-689. 
Young AM, Ahier RG, Upton RL, et al. (1998) Increased extracellular dopamine in the 
nucleus accumbens of the rat during associative learning of neutral stimuli. 
Neuroscience 83: 1175-1183. 
Young JW, Powell SB, Risbrough V, et al. (2009) Using the MATRICS to guide 
development of a preclinical cognitive test battery for research in schizophrenia. 
Pharmacol Ther 122: 150-202. 
Zanto TP, Rubens MT, Thangavel A, et al. (2011) Causal role of the prefrontal cortex in 
top-down modulation of visual processing and working memory. Nat Neurosci 
14: 656-661. 
 
